Is AbbVie Stock a Buy Now?
AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales growth and $2.12 in adjusted earnings per share (EPS), with both metrics exceeding initial guidance. Comments by management projected optimism for continued growth momentum into the new year.With the shares kicking off 2025 with a solid 8% gain year to date, some investors may wonder -- can the rally keep going, and is AbbVie stock a buy right now? Here's what you need to know.AbbVie is recognized as a leading drugmaker with an extensive portfolio of therapeutics in fields such as immunology, oncology, neuroscience, and eye care. Additionally, the company commercializes the high-profile aesthetics brands Botox and Juvederm as anti-aging skin treatments. This diversification, coupled with a long history of innovation, is a big part of what makes AbbVie a blue chip stock and compelling investment opportunity.Continue reading
AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales growth and $2.12 in adjusted earnings per share (EPS), with both metrics exceeding initial guidance. Comments by management projected optimism for continued growth momentum into the new year.
With the shares kicking off 2025 with a solid 8% gain year to date, some investors may wonder -- can the rally keep going, and is AbbVie stock a buy right now? Here's what you need to know.
AbbVie is recognized as a leading drugmaker with an extensive portfolio of therapeutics in fields such as immunology, oncology, neuroscience, and eye care. Additionally, the company commercializes the high-profile aesthetics brands Botox and Juvederm as anti-aging skin treatments. This diversification, coupled with a long history of innovation, is a big part of what makes AbbVie a blue chip stock and compelling investment opportunity.
